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INTRODUCTION
Frailty is a medical syndromemanifested by an increased vulner-
ability to minor stressors caused by a reduction in a person’s ho-
meostatic reserves [1]. It comprises domains such as nutritional
status, energy expenditure, metabolic rate, cognitive function
and sarcopenia. Frailty should be differentiated from ‘comorbid-
ity’ or ‘disability’ [2]. Patients without comorbidities can still be
frail, and although frailty leads to disability, a disabled person is
not necessarily frail. Elderly people are particularly susceptible to
developing frailty, but younger patients can be frail as well [3].
Frail patients are at a higher risk of death, become more de-
pendent on others and more often end up being institutional-
ized, compared with non-frail patients of the same age and with
a comparable number of comorbidities.
The relationship between chronic kidney disease (CKD) and
frailty is well established, and the degree of frailty in CKD and
end-stage kidney disease correlates with the quality of life and
survival [4]. By contrast, the relationship between acute kidney
injury (AKI) and frailty is less commonly studied. AKI and
frailty share common pathways and there seems to exist a bidi-
rectional relationship between the two conditions (Figure 1).
Predicted demographics show an increasing number of el-
derly people in parallel with an increasing number of patients at
risk for AKI, CKD and frailty. Hence, the concept of frailty
should be acknowledged in acute nephrology and included in
clinical decision-making.
On a societal, ethical and health economics level, there is
much to gain if frail patients could be identified for whom cer-
tain therapies could be considered futile and should be advised
against, such as starting renal replacement therapy (RRT) for
severe AKI.
THE BIDIRECTIONAL RELATIONSHIP
BETWEEN AKI AND FRAILTY
AKI often complicates critical illness and is associated with
high morbidity and mortality. AKI and frailty are likely to pre-
dispose to each other in a vicious circle, worsening a patient’s
outcome [5] (Figure 1).
The association between age, frailty and kidney disease is un-
surprising, considering the fact that the kidneys, like other organ
systems, go through a process of normal senescence that includes
both anatomical and physiological changes. These changes in a
normal ageing kidney are distinct from kidney diseases, which
are relatively common in the elderly. Elderly people are prone to
developing AKI [6] because they have more comorbidities, are
more often subjected to polypharmacy, which causes nephrotox-
icity, and have decreased homeostatic reserves. Frail patients
may be vulnerable to AKI through a common inflammatory re-
sponse, sharing similar characteristics such as high white blood
cell counts, low body mass index, and low haemoglobin and al-
bumin levels [7]. Not only do elderly frail patients have a higher
risk for AKI, but they also have less chances for recovery after an
AKI episode, compared with younger patients [8]. Frailty is an
independent predictor of AKI [7] and is associated with worse
outcome. Frail patients are also more likely to be discharged to a
nursing home [7]. Patients who are labelled as both having AKI
and being frail have the poorest outcome 1 year after discharge
[9]. An additional challenge in elderly frail patients lies in cor-
rectly diagnosing AKI. Serum creatinine (sCr) level becomes
even less reliable in the presence of sarcopenia, and it is expected
to decrease with age if the true glomerular filtration rate (GFR) is
unchanged. The rate and magnitude of an increase in sCr levels
may be blunted in the elderly because of lower muscle mass [10].
There also seems to be a J-shaped association between sCr levels
and functional limitation in elderly adults, even after adjusting
for muscle mass, demonstrating that sCr levels may be affected
by factors other than GFR and muscle mass in elderly adults
[11]. Creatinine may not simply be a product of muscle mass,
but its level may also be influenced bymuscle composition, activ-
ity, diet, health status and other factors.
The renal-specific contribution to frailty relates to factors
such as volume overload, anaemia, potential cognitive deficits,
medication toxicities and sarcopenia/muscle deconditioning. In
critical illness (ICU) survivors, an episode of AKI versus no
AKI predicted worse frailty scores at 3 and 12months post-dis-
charge, even after adjustment for severity of illness scores,
chronic underlying comorbidities, baseline kidney function and
baseline Clinical Frailty Scale (CFS) scores [12].
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However, the underlying mechanisms explaining the rela-
tionship between AKI and frailty are still largely unknown, and
future studies are needed to clarify whether the intersection of
AKI and frailty results from the kidneys acting as a sensitive
and easy-to-assess barometer of clinical status and/or from the
deleterious effects of AKI itself on health.
DISCUSSION
The majority of patients surviving critical illness will experience
reduced quality of life and/or greater dependency after hospital
discharge. Most studies have shown that health-related quality
of life is reduced in AKI versus no-AKI, patients, at least in
those treated with RRT [13, 14]. In one study [15], the majority
of patients described their quality of life as being worse than
death. The Study to Understand Prognoses and Preferences for
Outcomes and Risks of Treatments (SUPPORT) study [16]
demonstrated that overall, the estimated cost per quality-
adjusted life year (QALY) saved by initiating dialysis and con-
tinuing aggressive care, rather than withholding dialysis and
allowing death to occur, was $128 200. This is corroborated by
most other studies, although Laukkanen et al. [17] found that
the cost:utility ratio of acute RRT is poor, but acceptable, in
patients with renal recovery who survive for >1 year. However,
this is an unfair way to calculate QALYs, as the majority of frail
patients treated with RRT will not survive the first year after
hospital discharge [18, 19], and cost will thus be grossly under-
estimated. In a study by Wong et al. [20], patients aged
>85 years who started dialysis as inpatients and underwent at
least one other intensive care intervention had a median sur-
vival of 5months, of which 2 months were spent in hospital.
Around 10% of critically ill patients with AKI treated with
RRT will remain dialysis-dependent. This implies a risk factor
for worsening frailty and can explain the vicious circle between
frailty and kidney disease leading to increased dependency and
poor quality of life, especially in the elderly population.
Further research into what drives physicians to opt for ag-
gressive versus supportive care is necessary [19]. Bagshaw et al.
[18] demonstrated that there is a wide range of patient-specific
factors and differing clinician perception of the benefits of each
management approach, which would explain the heterogeneity
in willingness to offer RRT or not, and the reasons supporting
the decision-making. Frailty was more prevalent among older
patients to whom clinicians were less willing to offer dialysis.
One of the main conclusions of the study is that the most im-
portant risk faced by patients with severe AKI, irrespective of
whether they undergo dialysis or not, is death. Advanced age in
itself is rarely a reason for not starting dialysis. Unfortunately, a
physician’s decision to start or forgo dialysis mostly is not the
result of a shared decision-making process [18, 19].
The fact that frail patients with AKI have a poor outcome,
regardless of the therapy given, is an issue that needs to be better
addressed and discussed with patients. Informing patients
about their prognosis can make themwant to opt for supportive
care and optimize their time with family and loved ones, rather
than spend their last days in an intensive care environment in
vain. This is important from an ethical point of view, as it allows
personalized treatment, dignity in care and equitable use of
resources. Customizing treatment of patients with severe AKI
through shared decision-making is essential if we want to make
the switch from a paternalistic type of medicine towards a pa-
tient-centred approach.
To avoid futile care and non-rewarding spending of health-
care budgets [21, 22], while preserving dignity in patient care,
the following points merit some attention:
FIGURE 1: Graphic illustration of the relationship between frailty and kidney disease, the underlying pathophysiological mechanisms that are
likely involved and the overlap between the concepts of frailty, comorbidity and disability.
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(i) Caregivers should be aware of the importance of the
concept of frailty and acknowledge the important im-
pact frailty has on short- and long-term outcomes. On
admission into intensive care, the most appropriate tool
with which to assess frailty is the CFS [23].
(ii) Supportive care should be offered as a valuable option
to frail patients, e.g. the option of not starting RRT in
severe AKI [24, 25]. Many patients now state they did
not think that supportive therapy and forgoing dialysis
was an option.
(iii) Caregivers need guidance on how to have an open, con-
structive conversation with patients and/or their next-
of-kin about this topic. Proper communication (as al-
ways) is important, so that patients and their families
understand why a certain treatment is better not of-
fered. Often patients have unrealistic expectations about
their health status after admission into intensive care,
and this needs to be addressed. Speciﬁc tools should be
developed to aid physicians in this task.
(iv) AKI should not be regarded as a benign condition that
is easy reversible, especially in the frail patient [26].
This underlines the importance of a well-structured
transition of care. It is important to acknowledge the
special needs of frail patients and the advantages of a
multidisciplinary approach and coordinated specialist
services [27, 28]. Speciﬁc pharmacological and non-
pharmacological interventions should be explored in
frail patients, with a focus on rehabilitation, nutritional
interventions and exercise [29].
In the ICU, physicians are faced with extra challenges when
trying to comply with the above points. ICU patients are mostly
severely ill and incapacitated, which hinders direct communica-
tion and often, a surrogate decision-maker will have to make the
decisions. Regular re-evaluations should take place to assess
whether the patients themselves are able to be involved in the deci-
sion-making process. For an intensivist who often has little or no
insight into a patient’s background, assessing baseline frailty can
be difficult and hence a multidisciplinary approach involving all
caregivers is important. The role of the nursing team should not
be underestimated. They also should be in agreement with the
proposed line of action. Neglecting this aspect could lead to mis-
understandings in communication with the patient, and it could
also lead tomoral distress and burn-out within the team [30].
Since there is mostly no specific treatment for AKI (except
RRT), prevention of AKI is key. Prevention of frailty and/or its
progression could have an impact on AKI incidence. Potential
interventions that can reduce frailty mainly focus on exercise
(endurance, flexibility, balance and resistance training with
low-to-moderate intensity, in 30- to 45-min sessions, three
times a week), nutrition, medication reconciliation and organi-
zation of social support systems. Several pharmacological and
non-pharmacological interventions can be offered to frail
patients, but so far there is no hard evidence for the benefit of
any of these interventions.
Although prospective observational studies suggest a rela-
tionship between AKI and frailty, it is inherently impossible to
infer the causality between AKI and frailty from this study type.
There is a clear need for sufficiently powered randomized con-
trolled trials (RCTs) on interventions that reduce frailty and
subsequently AKI. Because AKI can occur due to multiple un-
derlying aetiologies, and even as a result of multiple hits at the
same time and across different settings, it is also possible that a
potential benefit might only be present in certain settings. More
research is needed to disentangle the complex relationship be-
tween AKI and frailty across these different settings and to fur-
ther unravel the underlying pathophysiology.
Research in this domain is expected to enhance awareness of
the concept of frailty and its relationship with AKI. There is a
need for standardization of the definition of frailty, so that it
can be used in a feasible way and across different settings such
as primary care, ambulatory care, acute care, critical care and
nursing home care. It is problematic that frail elderly patients
are often excluded from research since they are likely to respond
differently to interventions, compared with non-frail patients.
High-quality evidence could eventually lead to the development
of guidelines on how to organize a holistic approach in the care
of frail patients at risk for AKI and in AKI patients at risk for
frailty. This will hopefully lead to a customized approach, focus-
ing on the special needs of this vulnerable group of patients. On
a health economics level, the cost-effectiveness of such an ap-
proach in the long term should be evaluated.
CONCLUSION
Frailty, defined as exaggerated vulnerability to minor stressors,
is an independent predictor for AKI whereas, on the other
hand, non-frail patients who develop AKI are at risk for frailty.
In both CKD and AKI, frailty is associated with both short-
term and long-term adverse outcomes. Especially in the elderly,
there is a need for evaluation of the frailty status on hospital ad-
mission, and the presence of frailty should be considered when
making decisions on treatment such as whether or not to start
RRT in frail patients with severe AKI. Patients and/or their sur-
rogate decision-makers should be informed about the concept
of frailty and the impact it can have on survival, the degree of
dependency and the quality of life overall, empowering them to
make well-informed decisions about whether or not to opt for
aggressive versus supportive care. From both an ethical and a
health economics viewpoint, it is necessary to move away from
an imperative and paternalistic form of medicine and more to-
wards shared decision-making, which is crucial to every model
based on a patient-centred approach.
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